1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune

 
• By Alaric DeArment

The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.

• Source: Shutterstock

Cullinan Oncology, Inc. is changing course and increasing its focus on inflammation and immunology. The company will rebrand as Cullinan Therapeutics, Inc. as it moves CLN-978, its CD19xCD3-directed bispecific antibody, from B-cell non-Hodgkin lymphoma (B-NHL) to autoimmune diseases, starting with systemic lupus erythematosus (SLE).

Cambridge, MA-based Cullinan is just the latest of several oncology-focused companies to expand into rheumatology – particularly as the space for CD19-directed therapies and bispecific antibodies in NHL grows more

Key Takeaways

  • Cullinan Oncology has rebranded as Cullinan Therapeutics as the company moves into immunology in addition to its oncology focus.

  • The biotech is stopping development of the CD19-directed bispecific antibody CLN-978 in lymphomas and moving it into lupus and other autoimmune diseases

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

EU Approves Tremfya In Third Indication, Ulcerative Colitis

 
• By Sushmita Panda

J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.